Comments
Sun Pharma Consumer Healthcare, a division of Sun Pharmaceutical Industries , has entered the anti-fungal powder OTC category with Abzorb. The brand will be co-promoted across prescription and OTC channels in India to drive growth, Sun Pharma informed the exchanges.
Abzorb’s unique combination of talc and starch ensures superior sweat absorption and clotrimazole. The anti-fungal powder category is estimated to be worth over ₹100 crore in India (IMS MAT August 2017) and Abzorb is a key player in the segment. Inconsistent weather conditions with increasing instances of high temperatures and unexpected rain have increased the incidence of fungal infections with the category growing at over 15 per cent every year. Shares of Sun Pharma closed at ₹528.40, a gain of 0.8 per cent on the NSE.
Comments
Comments
Comments have to be in English, and in full sentences. They cannot be abusive or personal. Please abide by our community guidelines for posting your comments.
We have migrated to a new commenting platform. If you are already a registered user of TheHindu Businessline and logged in, you may continue to engage with our articles. If you do not have an account please register and login to post comments. Users can access their older comments by logging into their accounts on Vuukle.